Literature DB >> 24506465

Increased plasma advanced oxidation protein products is an early marker of endothelial dysfunction in type 2 diabetes patients without albuminuria 2.

Min Liang1, Jun Wang, Chao Xie, Yan Yang, Jian Wei Tian, Yao Ming Xue, Fan Fan Hou.   

Abstract

BACKGROUND: Endothelial dysfunction is an early event of cardiovascular disease in type 2 diabetes (T2D) and can occur before albuminuria. Oxidative stress has been found to play a key role in the development of endothelial dysfunction. Therefore, we hypothesized that increases in plasma advanced oxidized protein products (AOPPs), a family of oxidized, dityrosine-containing protein compounds generated during oxidative stress, could serve as an early marker of endothelial dysfunction in T2D patients without albuminuria.
METHODS: We conducted a cross-sectional investigation of 147 newly diagnosed T2D patients (112 without albuminuria and 35 with albuminuria) and 49 age-matched healthy control subjects. Flow-mediated vasodilation (FMD) was used to assess endothelium-dependent vasodilator function, and plasma soluble intercellular adhesion molecule-1 (sICAM-1) concentrations were determined to evaluate vascular injury. Plasma AOPPs concentrations were measured using a modified spectrophotometric assay.
RESULTS: Plasma AOPPs concentrations were significantly elevated in normoalbuminuric patients with T2D compared with healthy controls. Plasma AOPPs concentrations were correlated with FMD and plasma sICAM-1 concentrations in this population. Multivariate regression analysis demonstrated that increased plasma AOPPs was the strongest risk factor for impaired endothelial vasodilation and increased sICAM-1 in these patients. Similar results were observed in T2D patients with albuminuria.
CONCLUSIONS: Increased plasma AOPPs concentrations were an independent risk factor for endothelial dysfunction, and therefore may be an early marker of vasculopathy in individuals at an early stage of diabetes.
© 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  advanced oxidation protein products; endothelial dysfunction; normoalbuminuria; type 2 diabetes mellitus; 关键词:晚期蛋白氧化产物,内皮细胞功能异常,正常尿白蛋白,2型糖尿病

Mesh:

Substances:

Year:  2014        PMID: 24506465     DOI: 10.1111/1753-0407.12134

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  5 in total

1.  Plasma Markers of Oxidative Stress in Patients with Gestational Diabetes Mellitus in the Second and Third Trimester.

Authors:  Hongwei Li; Qian Yin; Ning Li; Zhenbo Ouyang; Mei Zhong
Journal:  Obstet Gynecol Int       Date:  2016-10-10

2.  Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy.

Authors:  Giovanni Conti; Daniela Caccamo; Rossella Siligato; Guido Gembillo; Ersilia Satta; Dario Pazzano; Nicolina Carucci; Antonio Carella; Giuliana Del Campo; Antonino Salvo; Domenico Santoro
Journal:  Medicina (Kaunas)       Date:  2019-10-07       Impact factor: 2.430

3.  Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus.

Authors:  Elisabetta Bigagli; Cristina Luceri; Ilaria Dicembrini; Lorenzo Tatti; Francesca Scavone; Lisa Giovannelli; Edoardo Mannucci; Maura Lodovici
Journal:  Antioxidants (Basel)       Date:  2020-03-11

4.  [Association of plasma level of advanced oxidation protein products with Framingham risk score in type 2 diabetic patients without vascular diseases].

Authors:  Chao Xie; Jie Tian; Wei Li; Min Liang; Yao-Zhong Kong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

5.  The Relationship between Advanced Oxidation Protein Products, Vascular Calcifications and Arterial Stiffness in Predialysis Chronic Kidney Disease Patients.

Authors:  Ion-Vlad Vinereanu; Ileana Peride; Andrei Niculae; Andreea Taisia Tiron; Andra Caragheorgheopol; Dana Manda; Ionel Alexandru Checherita
Journal:  Medicina (Kaunas)       Date:  2021-05-06       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.